Taranabant, a novel cannabinoid type 1 receptor inverse agonist

Current Opinion in Investigational Drugs

Volumn 9, Issue 10, 2008, Pages 1116-1129

  Fremming, B A ^a   Boyd, S T ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; DIGOXIN; ETHINYLESTRADIOL PLUS NORGESTIMATE; FLUORINE 18; MK 9470; PLACEBO; RIMONABANT; SIBUTRAMINE; TARANABANT; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG; WARFARIN;

AREA UNDER THE CURVE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CRYING; DECREASED APPETITE; DEFECATION; DEPRESSION; DIAPHORESIS; DIZZINESS; DROWSINESS; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HICCUP; HUMAN; HYPERTENSION; INAPPROPRIATE LAUGHING; INSOMNIA; LOOSE FECES; MENTAL INSTABILITY; MOOD CHANGE; MUSCLE CRAMP; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; QT PROLONGATION; REVIEW; SADNESS; SEROTONIN SYNDROME; SIDE EFFECT; SINGLE DRUG DOSE; SMOKING CESSATION; STEATORRHEA; STOMACH PAIN; TOBACCO DEPENDENCE; VOMITING; WEIGHT REDUCTION;

AMIDES; ANIMALS; ANTI-OBESITY AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG INDUSTRY; HUMANS; OBESITY; PATENTS AS TOPIC; PYRIDINES; RECEPTOR, CANNABINOID, CB1; STRUCTURE-ACTIVITY RELATIONSHIP; TOBACCO USE DISORDER;

EID: 53049108013     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. 2 receptors. Pertwee RG PHARMACOL THER 1997 74 2 129-180
2. 338336 Cannabinoid receptor interactions with the antagonists SR-141716A and SR-144528. Shire D, Calandra B, Bouaboula M, Barth F, Rinaldi Carmona M, Casellas P, Ferrara P LIFE SCI 1999 65 6-7 627-635
3. 1) receptors. Williams CM, Kirkham TC PSYCHOPHARMACOLOGY 1999 143 3 315-317
4. 397079 Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC J NEUROSCI 1991 11 2 563-583
5. 479672 Obesity market overview. Farrigan C, Pang K NAT REV DRUG DISCOV 2002 1 4 257-258
6. 496182 Endogenous cannabinoid system as a modulator of food intake. Cota D, Marsicano G, Lutz B, Vicennati V, Stalla GK, Pasquali R, Pagotto U INT J OBESITY RELAT METAB DISORD 2003 27 3 298-301
7. 527531 Experimental drugs take aim at obesity. Vastag B J AM MED ASSOC 2003 289 14 1763-1764
8. 1 cannabinoid receptor antagonists. Lange JH, Kruse CG DRUG DISC TODAY 2005 10 10 693-702
9. 650735 Company pipeline: Merck and Co Inc. Merck & Co Inc COMPANY WORLD WIDE WEB SITE 2005 December 15
10. 651048 sanofi-aventis's rimonabant NDAs get mixed response from FDA. sanofi-aventis PRESS RELEASE 2006 February 17
11. 653125 NCT00109135: A study to investigate a research drug as an aid for smoking cessation in chronic cigarette smokers. Merck & Co Inc CLINICALTRIALS.GOV 2006 March 01
12. 653252 NCT00109148: An investigational drug study in obese (considerably overweight) patients. Merck & Co Inc CLINICALTRIALS. GOV 2006 March 01
13. 1 receptor inverse agonists. Plummer CW, Finke PE, Mills SG, Wang J, Tong X, Doss A, Fong TM, Lao JZ, Schaeffer MT, Chen J, Shen CP et al BIOORG MED CHEM LETT 2005 15 5 1441-1446
14. 1 receptor inverse agonists. Debenham JS, Madsen-Duggan CB, Walsh TF, Wang J, Tong X, Doss GA, Lao J, Fong TM, Schaeffer MT, Xiao JC, Huang CR et al BIOORG MED CHEM LETT 2006 16 3 681-685
15. 733442 Merck announces strong financial results for the third quarter 2006 led by the performance of SINGULAIR, VYTORIN and vaccines. Merck & Co Inc PRESS RELEASE 2006 October 20
16. 766650 Drug development for obesity - A Marcus Evans conference, key strategies for effective drug discovery, London, UK, 12-13 February 2007. Collins T IDDB MEETING REPORT 2007 February 12-13
17. 783584 NCT00430742: A one year investigational drug study to assess weight loss in patients with type 2 diabetes mellitus. Merck & Co Inc CLINICALTRIALS.GOV 2007 May 09
18. 804452 FDA advisors reject sanofi-aventis's Zimulti obesity drug. sanofi-aventis PRESS RELEASE 2007 June 13
19. 811710 Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1- methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy} propanamide (MK-0364), in rodents. Fong TM, Guan XM, Marsh DJ, Shen CP, Stribling DS, Rosko KM, Lao J, Yu H, Feng Y, Xiao JC, Van der Ploeg LHT et al J PHARMACOL EXP THER 2007 321 3 1013-1022
20. 817950 Synthesis of isotopically labeled 2-pyridinyloxyisobubanoic acid, a building block for CB-1 inhibitors as drug candidates for obesity treatment. Ho JZ, Braun MP AM CHEM SOC NATL MEET EXPOSITION 2007 234 Medi-33
21. 832033 Advances in structure-based drug discovery - Second ACS Prospectives conference, San Francisco, CA, USA, 9-11 September 2007. Kulczynska A IDDB MEETING REPORT 2007 September 9-11
22. 838846 Blocking the cannabinoid receptors: Drug candidates and therapeutic promises. Muccioli GG CHEM BIODIVERS 2007 4 8 1805-1827
23. 1 receptor by receptor mutagenesis. Xiao J, Lin L, Hagmann W, Fong TM, Shen CP SOC NEUROSCI ANN MEET 2007 37 November 07 Abs 878.8
24. 855652 Efficacy and safety of the weight-loss drug rimonabant: A meta-analysis of randomised trials. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A LANCET 2007 370 9600 1706-1713
25. 870352 Drug discovery conference 2008, small molecule drug discovery: From early-stage to the clinic, Antigua, 17-20 January 2008. Terrett NK IDDB MEETING REPORT 2008 January 17-20
26. 871453 Convenient total synthesis of taranabant (MK-0364), a novel cannabinoid-1 receptor inverse agonist as an anti-obesity agent. Kim M, Kim JY, Song KS, Kim J, Lee J TETRAHEDRON 2007 63 52 12845-12852
27. 887489 Influence of taranabant, a novel cannabinoid 1 receptor (CB-1R) inverse agonist, on the pharmacokinetics and pharmacodynamics of warfarin. Schwartz J, Yuan J, Li S, Gipson A, Rosko K, Zakson M, Lasseter KC, Wagner JA CLIN PHARMACOL THER 2008 83 Suppl 1 Abs S22
28. 891617 Merck & Co's taranabant effective in phase III obesity trial. Merck & Co Inc PRESS RELEASE 2008 March 31
29. 895185 Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: Results from a double-blind, placebo-controlled, single oral dose study in healthy volunteers. Addy C, Li S, Agrawal N, Stone J, Majumdar A, Zhong L, Li H, Yuan J, Maes A, Rothenberg P, Cote J et al J CLIN PHARMACOL 2008 48 4 418-427
30. 897795 Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl] -2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist. Lin LS, Ha S, Ball RG, Tsou NN, Castonguay LA, Doss GA, Fong TM, Shen CP, Xiao JC, Goulet MT, Hagmann WK J MED CHEM 2008 51 7 2108-2114
31. 905703 Taranabant exhibits no clinically meaningful effect on the pharmacokinetic profile of digoxin. Denker AE, Vessey L, Li XS, Yuan J, Agrawal NG, Dunbar S, Wagner JA CLIN PHARMACOL THER 2008 83 Suppl 1 Abs PIII-70
32. 905704 The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Addy C, Wright H, Van Laere K, Gantz I, Erondu N, Musser BJ, Lu K, Yuan J, Sanabria-Bohorquez SM, Stoch A, Stevens C et al CELL METAB 2008 7 1 68-78
33. 18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Burns HD, Van Laere K, Sanabria-Bohorquez S, Hamill TG, Bormans G, Eng W, Gibson R, Ryan C, Connolly B, Patel S, Krause S et al PROC NATL ACAD SCI USA 2007 104 23 9800-9805
34. 905708 Substituted acyclic sulfonamides as human cannabinoid-1 receptor inverse agonists. Armstrong HE, Galka A, Lin LS, Lanza TJJ, Jewell JP, Shah SK, Guthikonda R, Truong Q, Chang LL, Quaker G, Colandrea VJ et al BIOORG MED CHEM LETT 2007 17 8 2184-2187
35. 1 receptor inverse agonists Madsen-Duggan CB, Debenham JS, Walsh TF, Toupence RB, Huang SX, Wang J, Tong X, Lao J, Fong TM, Schaeffer MT, Xiao JC et al BIOORG MED CHEM LETT 2007 17 7 2031-2035
36. 905710 Influence of taranabant, a novel cannabinoid-1 receptor (CB-1R) inverse agonist, on ethinyl estradiol and norelgestromin pharmacokinetics. Schwartz JI, Yuan J, Li S, Miller DL, Rosko K, Zakson M, Lasseter KC, Wagner JA J CLIN PHARMACOL 2007 47 9 1192
37. 905711 Clinical evaluation of brain CB-1 receptor occupancy of a novel CB1R inverse agonist using CB-1R PET. Addy C, Rothenberg P, Burns D, Sanabria S, Eng WS, De Lepeleire I, Van Dyck K, Cote J, Rosko K, Bormans G, De Hoon J et al DIABETES 2007 56 Suppl 1 Abs 2738-PO
38. 905712 MK-0364, a CB-1R inverse agonist, reduces acute food intake in overweight/obese male volunteers Stevens C, Cilissen C, De Smet M, Krupa D, Larson P, De Decker M, Herman G, Wagner J, Wright H DIABETES 2007 56 Suppl 1 Abs 1830-P
39. 905713 MK-0364, a novel cannabinoid-1 receptor inverse agonist, increases energy expenditure in overweight and moderately obese subjects. Addy C, Heymsfield S, Cilissen C, Gendrano IN, De Smet M, De Decker M, Yuan J, Larson P, Dunbar S, Stoch A, Wagner J DIABETES 2007 56 Suppl 1 Abs 1828-P
40. 905714 The CB-1R inverse agonist taranabant reduces acute food intake in overweight/obese male volunteers Wright D, Stevens C, Cilissen C, De Smet M, Krupa D, Larson P, De Decker M, Herman G, Wagner J DIABETOLOGIA 2007 50 Suppl 1 Abs 0833
41. 905715 Taranabant increases energy expenditure in overweight and moderately obese subjects De Decker M, Yuan J, Larson P, Dunbar S, Stoch A, Wagner J, Addy C, Heymsfield S, Cilissen C, Gendrano IN, De Smet M DIABETOLOGIA 2007 50 Suppl 1 Abs 0832
42. 905716 Brain CB-1 receptor occupancy of taranabant in lean subjects using CB-1R PET. De Lepeleire I, Addy C, Rothenberg P, Burns D, Sanabria S, Eng W, Bormans G, Depre M, Mortelmans L, Dupont P, Stoch A et al DIABETOLOGIA 2007 50 Suppl 1 Abs 0831
43. 905717 Discovery of a novel CB1R inverse agonist (MK-0364) for the treatment of obesity. Fong T, Guan X-M, Marsh D, Shen C-P, Lao J, Stribling DS, Rosko K, Yu H, Feng Y, Xiao J, Van Der Ploeg LHT et al INT J OBESITY 2007 31 Suppl 1 S87
44. 905720 Discovery of N-[(1S,2S)-3-(4-chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl) pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity. Lin LS, Lanza TJJ, Jewell JP, Liu P, Shah SK, Qi H, Tong X, Wang J, Xu SS, Fong TM, Shen CP et al J MED CHEM 2006 49 26 7584-7587
45. 906243 Meeting highlights from the Paediatric Committee, 6-8 May 2008. European Agency for the Evaluation of Medicinal Products PRESS RELEASE 2008 May 15
46. 914223 Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers. Addy C, Rothenberg P, Li S, Majumdar A, Agrawal N, Li H, Zhong L, Yuan J, Maes A, Dunbar S, Cote J et al J CLIN PHARMACOL 2008 48 6 734-744
47. 931204 The discovery of taranabant, a selective cannabinoid-1 receptor inverse agonist for the treatment of obesity. Hagmann WK ARCH PHARM 2008 341 7 405-411
48. 933852 Obesity: Epidemiology and clinical aspects. Formiguera X, Canton A BEST PRACT RES CLIN GASTROENTEROL 2004 18 6 1125-1146
49. 933905 The obesity epidemic, metabolic syndrome and future prevention strategies. James PT, Rigby N, Leach R EUR J CARDIOVASC PREVENT REHABIL 2004 11 1 3-8
50. 933909 Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM J Am Med Assoc 2004 291 23 2847-2850
51. 933910 The obesity epidemic: Incidence and prevalence. Webber LS, Bedimo-Rung AL J LA STATE MED SOC 2005 157 1 3-11
52. 933911 The endocannabinoid system: Physiology and pharmacology. Rodriguez de Fonseca F, Del Arco I, Bermudez-Silva FJ, Bilbao A, Cippitelli A, Navarro M ALCOHOL 2005 40 1 2-14
53. 933912 Cannabimimetic fatty acid derivatives: The anandamide family and other endocannabinoids Di Marzo V, Bisogno T, De Petrocellis L, Melck D, Martin BR CURR MED CHEM 1999 6 8 721-744
54. 933922 The cannabinoid receptors. Howlett AC PROSTAG OTHER LIPID MEDIAT 2002 68-69 619-631
55. 933928 Cannabinoid physiology and pharmacology: 30 years of progress. Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ NEUROPHARMACOLOGY 2004 47 Suppl 1 345-358
56. 933930 Endocannabinoids: Endogenous cannabinoid receptor ligands with neuromodulatory action. Di Marzo V, Melck D, Bisogno T, De Petrocellis L TRENDS NEUROSCI 1998 21 12 251-258
57. 2), their distribution, ligands and functional involvement in nervous system structures - a short review. Svizenska I, Dubovy P, Sulcova A PHARMACOL BIOCHEM BEHAV 2008 90 4 501-511
58. 933934 Cannabinoid antagonists: A treatment in search of an illness. D'Souza DC, Kosten TR ARCH GEN PSYCHIATRY 2001 58 4 330-331
59. 1 inverse agonists. Foloppe N, Allen NH, Bentley CH, Brooks TD, Kennett G, Knight AR, Leonardi S, Misra A, Monck NJ, Sellwood DM BIOORG MED CHEM LETT 2008 18 3 1199-1206
60. 934418 The many roles for fluorine in medicinal chemistry. Hagmann WK J MED CHEM 2008 51 15 4359-4369
61. 934421 NCT00109135: A study to investigate a research drug as an aid for smoking cessation in chronic cigarette smokers. CLINICALTRIALS.GOV 2008
62. 934423 NCT00131404: A two year safety and efficacy study in obese patients. CLINICALTRIALS.GOV 2008
63. 934428 NCT00131430: An eighteen month efficacy and safety study in obese patients. CLINICALTRIALS.GOV 2008
64. 934431 NCT00131391: A study of MK0364 in obese patients. CLINICALTRIALS.GOV 2008
65. 934434 Phase III data for investigational drug taranabant in treatment of obesity. Pocock N; National Electronic Library for Medicines INTERNET SITE 2008 April 02
66. 938174 Prescribing information: Meridia. Abbott Laboratories COMPANY PUBLICATION 2008 August 26
67. 938184 Prescribing information: Xenecal (orlistat). Hoffmann-La Roche Inc COMPANY PUBLICATION 2008 August 26
68. 938398 Cannabinoid receptors in invertebrates. McPartland JM, Agraval J, Gleeson D, Heasman K, Glass M J EVOL BIOL 2006 19 2 366-373
69. 938404 The endocannabinoid system as an emerging target of pharmacotherapy. Pacher P, Bátkai S, Kunos G PHARMACOL REV 2006 58 3 389-462
70. 938405 Neurobiology cannabinoids act backwards. Christie MJ, Vaughan CW NATURE 2001 410 6828 527-530
71. 1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Bátkai S, Harvey-White J, Mackie K, Offertáler L, Wang L, Kunos G J CLIN INVEST 2005 115 5 1298-1305
72. 938502 Neuropharmacology of the endocannabinoid signaling system - Molecular mechanisms, biological actions and synaptic plasticity. Basavarajappa BS CURR NEUROPHARMACOL 2007 5 2 81-97
73. 938789 Effects of taranabant, a novel cannabinoid 1 receptor (CB-1R) inverse agonist, on weight reduction in obese patients over 12 weeks. McKenney JM, Carr RD, Erondu N, Gonzalez CD, Gumbiner B, Musser B, Lu K, Capece RA, Klein S, Ravussin E, Amatruda JM, Heymsfield SB INT J OBESITY 2008 32 Suppl 1 Abs T2:PS.09
74. 938790 A two-year study to assess the efficacy, safety, and tolerability of taranabant in obese patients: 52 week results. Proietto J, Gantz I, Carr RD, Erondu N, Moreno M, Suryawanshi S, Musser B, Nayee J, Johnson-Levonas AO, Heymsfield S, Amatruda J INT J OBESITY 2008 32 Suppl 1 Abs T2:OS3.1
75. 938791 A two-year study to assess the efficacy, safety, and tolerability of taranabant in obese patients: 52 week results. Gantz I, Erondu N, Suryawanshi S, Musser B, Nayee J, Johnson-Levonas AO, Heymsfield S, Amatruda J J AM COLL CARDIOL 2008 51 10 Abs 1021-220
76. 938800 The efficacy and tolerability of taranabant, a cannabinoid receptor inverse agonist, over 24 weeks in obese patients. Davidson MH, McKenney JM, Bays HE, Shentu Y, Lu K, Suryawanshi S, Heymsfield SB, Evans JK, Cruz S, Erondu N, Amatruda JM et al INT J OBESITY 2008 32 Suppl 1 Abs T2:PS.37
77. 938962 NCT00420589: A weight maintenance study in obese patients. CLINICALTRIALS.GOV 2008
78. 938965 NCT00384605: A one year investigational drug study to assess weight loss in obese and overweight patients. CLINICALTRIALS.GOV 2008
79. 938966 NCT00430742: A one year investigational drug study to assess weight loss in patients with type 2 diabetes mellitus. CLINICALTRIALS. GOV 2008
80. 1 antagonist on the control of metabolic functions in obese type 2 diabetic patients. Lafontan M, Piazza PV, Girard J DIABETES METAB 2007 33 2 85-95